Search | Clinical Trials Finder

Conditions: Primary Sclerosing Cholangitis
Interventions: Cilofexor, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 82
States / cities: Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Fenebrutinib, Teriflunomide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 12
States / cities: Cullman, Alabama • Phoenix, Arizona • Torrance, California + 9 more

Conditions: Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions: Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr; Drug
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Mycobacterium Avium-Intracellulare Infection
Interventions: Interferon Gamma for Aerosol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Diabetes, Insulin Resistance
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Participants
Interventions: Eplontersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Leg Ulcer
Interventions: CO2RE® (Syneron Candela Corp, Wayland, MA), Sham laser treatment; Device · Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: IgA Nephropathy, Berger Disease
Interventions: Atacicept, Placebo to match Atacicept; Biological · Other
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Pemphigus
Interventions: Infliximab, Placebo Comparator; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more

Conditions: Depression
Interventions: NSI-189 Phosphate; Drug
Lead sponsor: Neuralstem Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: PostTraumatic Stress Disorder
Interventions: Ropivacaine, Sham treatment; Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Honolulu, Hawaii • Fort Bragg, North Carolina

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: CPVT1, Heart Defects, Congenital, Heart Diseases, Ventricular Tachycardia
Interventions: CRD-4730, Placebo; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Cincinnati, Ohio • Cleveland, Ohio • Houston, Texas

Conditions: Depression
Interventions: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI); Drug · Other · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Peripheral Artery Disease (D058729), Oxidative Stress (D018384), Inflammation (D007249)
Interventions: PB125, Placebo, Exercise Rehabilitation; Dietary Supplement · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Chronic Kidney Disease
Interventions: HEPLISAV-B, Engerix-B, Placebo; Biological · Other
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Group B Streptococcus Infections
Interventions: Multivalent Group B streptococcus vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years to 40 Years
Enrollment: 1,208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 26
States / cities: Mobile, Alabama • Phoenix, Arizona • Lancaster, California + 11 more

Conditions: Opioid Withdrawal, Pain, Craving
Interventions: Active BRIDGE device placement, Inactive BRIDGE device placement; Device
Lead sponsor: BrightView LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Treprostinil Inhalation Solution, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions: Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more

Conditions: Erythropoietic Protoporphyria (EPP)
Interventions: PORT-77, Placebo; Drug
Lead sponsor: Portal Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Zika Virus Infection
Interventions: IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Search by objective public record fields.

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants

Evaluating the Safety and Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Atacicept in Subjects With IgA Nephropathy

Use of Infliximab for the Treatment of Pemphigus Vulgaris

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

Improving Exercise Rehabilitation Efficacy Outcomes Veterans Peripheral Artery Disease

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

BRIDGE Device for Treatment of Opioid Withdrawal

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NATIENS: Optimal Management and Mechanisms of SJS/TEN

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.